GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (MEX:SNY N) » Definitions » Moat Score

Sanofi (MEX:SNY N) Moat Score : 8/10 (As of Jul. 14, 2025)


View and export this data going back to 2009. Start your Free Trial

What is Sanofi Moat Score?

Sanofi has the Moat Score of 8, which implies that the company might have Wide Moat - Clear and robust wide moat.

Sanofi has Wide Moat: Sanofi SA possesses a robust portfolio of patented drugs, strong brand recognition, and significant R&D capabilities. These factors, combined with regulatory barriers and pricing power, provide a clear and robust wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Sanofi might have Wide Moat - Clear and robust wide moat.

Competitive Comparison of Sanofi's Moat Score

For the Drug Manufacturers - General subindustry, Sanofi's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sanofi's Moat Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sanofi's Moat Score distribution charts can be found below:

* The bar in red indicates where Sanofi's Moat Score falls into.


;
;

Sanofi  (MEX:SNY N) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Sanofi Moat Score Related Terms

Thank you for viewing the detailed overview of Sanofi's Moat Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Sanofi Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (MEX:SNY N) » Definitions » Moat Score
Comparable Companies
XPAR:VIRP LLY JNJ ABBV OCSE:NOVO B XSWX:ROG XSWX:NOVN LSE:AZN MRK AMGN GILD PFE BMY TSE:4519 LSE:GSK SHSE:600276 TSE:4568 XTER:BAYN TSE:4578 BIIB
Traded in Other Exchanges
SNYNF:USA SNY:USA 1SAN:Italy 0A2V:UK SANp:UK 0O59:UK SAN:France SNW:Germany SNW2:Germany SNW:Germany SNW:Germany SNW2:Germany SNW:Germany SNW:Bulgaria SANO:Austria
Address
46, Avenue de la Great Army, Paris, FRA, 75017
Website
https://www.sanofi.com
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Sanofi Headlines

No Headlines